Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection – A prospective cross-sectional study

Table 2 Patient Characteristics [data given as number (%) or median (range)]

	HCV-infection(Group I)	HIV-infection(Group II)	HCV/HIV-coinfection(Group III)	Statistical significance
Number	112	85	121
Sex (Male / female)	108 / 4	73 / 12	117 / 4	Group I vs II P = 0.009*; group II vs III P = 0.007*
Age (median, range)	39 (13 - 77)	38 (23 - 70)	37 (21 - 62)
Risk factors (%)
Sexual	- - -	62 (72.9)	1 (0.8)	Group I vs II and II vs III P < 0.001*
Endemic	- - -	5 (5.9)	- - -	Group I vs II P = 0.009*; group II vs III P = 0.011*
I.V. drugs	- - -	4 (4.7)	3 (2.4)	Group I vs II P = 0.023*
Blood transfusion	- - -	1 (1.2)	- - -
Hemophilia	110 (98.2)	- - -	115 (95.0)	Group I vs II P < 0.001*; group II vs III P < 0.001*
Unknown	2 (1.8)	13 (15.3)	2 (1.7)	Group I vs II P < 0.001*; group II vs III P < 0.001*
Aminotransferase activities
ALT U/L (median, range)	34.0 (5.2 - 226.0)	17.0 (7.0 - 84.0)	38.5 (1.0 - 214.0)	Group I vs II and II vs III P < 0.001
AST U/L (median, range)	19.0 (5.8 - 157.0)	12.0 (4.3 - 106.0)	26.1 (7.8 - 168.0)	Group I vs II P = 0.002; group I vs III P = 0.030;
				Group II vs III P < 0.001
GGT U/L (median, range)	25.2 (5.2 - 350.9)	17.0 (6.2 - 149.0)	42.0 (2.9 - 254.6)	Group II vs III P < 0.001
HIV-status
CD4 count (median, range)	668 (171 - 2 039)/µL	350 (5 - 1 142)/µL	292.5 (6 - 1 219)/µL	Group I vs II and I vs III P < 0.001
CD8 count (median, range)	499 (62 - 1 653)/µL	931 (88 - 2 152)/µL	804 (39 - 3 056)/µL	Group I vs II and I vs III P < 0.001
HIV load (median, range)	- - -	300 (<80 - 830 000)	725 (<80 - 210,000)
HIV-viremia < 80 copies/mL	- - -	47 (55.3%)	80 (66.1%)
Type of antiretroviral Therapy (%)
Protease inhibitor-based HAART	- - -	62 (72.9)	58 (47.9)	Group II vs III P = 0.001
NNRTI-based HAART	- - -	11 (12.9)	25 (20.7)
Total	- - -	73 (85.9)	83 (68.6)	Group II vs III P = 0.007
HCV-status
HCV load (copies/mL)	8 888 000 (n.d.-126,500,000)	- - -	13 535 000 (n.d.-178 900 000)	Group I vs III P = 0.012
HCV load (IU/mL)	1 410 794 (n.d.-20,079,365)	- - -	2 148 413 (n.d.-28 396 825)
HCV-genotypes (%)
Genotype 1	70 (62.5)	- - -	76 (62.8)
Genotype 2	14 (12.5)	- - -	11 (9.1)
Genotype 3	8 (7.1)	- - -	21 (17.4)	Goups I vs III P = 0.028*
Genotype 4	6 (5.4)	- - -	5 (4.1)
Multiple genotypes	1 (0.9)	- - -	1 (0.8)
Undeterminded genotype	13 (11.6)	- - -	7 (5.8)
HBV-status (%)
Anti-HBs+ and anti-HBc+	52 (46.4)	15 (17.6)	43 (35.5)
Anti-HBc+ alone	10 (8.9)	5 (5.9)	34 (28.1)	Group I vs II P < 0.001; group II vs III P = 0.008
HBs-Ag+	1 (0.9)	3 (3.5)	6 (5.0)	Group I vs III P < 0.001; group II vs III P < 0.001*

* Fisher´s exact test; n.d. = not detected.